Back to Journals » Infection and Drug Resistance » Volume 1

Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles

Authors Laohavaleeson S, Lolans K, Quinn JP, Kuti JL, Nicolau DP

Published 23 November 2008 Volume 2008:1 Pages 51—55

DOI https://doi.org/10.2147/IDR.S4418

Review by Single-blind

Peer reviewer comments 2

Somvadee Laohavaleeson1, Karen Lolans2,3, John P Quinn2,3,4, Joseph L Kuti1, David P Nicolau1

1Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA; 2John Stroger Hospital, Chicago, IL, USA; 3Chicago Infectious Disease Research Institute, Chicago, IL, USA; 4Rush University Medical Center, Chicago, IL, USA

Abstract: While MIC distributions and percent susceptibility for cefepime and ceftazidime are generally similar among Pseudomonas aeruginosa, we noted an increasing discordance in susceptibility favoring ceftazidime at our hospital. Quantitative reverse transcriptase-polymerase chain reaction was utilized to explore overexpression of the MexXY-OprM efflux as the mechanism for this phenotype profile. Thirteen of 15 (87%) randomly selected isolates had mexY gene expression levels of 5.8–40.8-fold relative to the wild-type reference strain. While mexY overexpression was noted in the majority of isolates, other resistance mechanisms appear to contribute to the observed phenotypic profile of the Pseudomonas aeruginosa studied. Clinicians must understand not only the magnitude of difference in the MIC profiles between agents, but also the mechanism(s) responsible for these observations if strategies (ie, pharmacodynamic dosing) are to be designed to optimize patient care outcomes in the face of increasing resistance.

Keywords: Pseudomonas aeruginosa, efflux, MexXY-OprM, mexY, cefepime, resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

blaCTX-M-I group extended spectrum beta lactamase-producing Salmonella typhi from hospitalized patients in Lagos, Nigeria

Akinyemi KO, Iwalokun BA, Alafe OO, Mudashiru SA, Fakorede C

Infection and Drug Resistance 2015, 8:99-106

Published Date: 11 May 2015

The effect of a unique propolis compound (PropoelixTM) on clinical outcomes in patients with dengue hemorrhagic fever

Soroy L, Bagus S, Yongkie IP, Djoko W

Infection and Drug Resistance 2014, 7:323-329

Published Date: 9 December 2014

Long-term catheterization: current approaches in the diagnosis and treatment of port-related infections

Bustos C, Aguinaga A, Carmona-Torre F, Del Pozo JL

Infection and Drug Resistance 2014, 7:25-35

Published Date: 18 February 2014

Management strategies in the treatment of neonatal and pediatric gastroenteritis

Ciccarelli S, Stolfi I, Caramia G

Infection and Drug Resistance 2013, 6:133-161

Published Date: 29 October 2013

Overview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistance

Chen LF, Anderson DJ, Paterson DL

Infection and Drug Resistance 2012, 5:133-141

Published Date: 24 September 2012

A necrotic lung ball caused by co-infection with Candida and Streptococcus pneumoniae

Yokoyama T, Sasaki J, Matsumoto K, Koga C, Ito Y, Kaku Y, Tajiri M, Natori H, Hirokawa M

Infection and Drug Resistance 2011, 4:221-224

Published Date: 15 December 2011